Patents by Inventor Heidi Lopez de Diego

Heidi Lopez de Diego has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of a MAGL inhibitor
    Patent number: 12152029
    Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: November 26, 2024
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Vetter, Martin Juhl, Heidi Lopez De Diego, Cheryl A. Grice, John J. M. Wiener, Daniel J. Buzard, Amy Allan, Susana Del Rio Gancedo, Samuel George Andrew, Antonio Cincotti, Adam Ross Patterson, Richard James Edwards
  • SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID
    Publication number: 20240190909
    Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
    Type: Application
    Filed: November 16, 2023
    Publication date: June 13, 2024
    Applicant: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez De Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fog Jacobsen
  • Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
    Patent number: 11858954
    Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: January 2, 2024
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez de Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fog Jacobsen
  • CRYSTALLINE FORMS OF A MAGL INHIBITOR
    Publication number: 20230265095
    Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)b enzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 1, 2022
    Publication date: August 24, 2023
    Inventors: Thomas VETTER, Martin JUHL, HEIDI LOPEZ DE DIEGO, Cheryl A. GRICE, John J.M. WIENER, Daniel J. BUZARD, Amy ALLAN, Susana DEL RIO GANCEDO, Samuel George ANDREW, Antonio CINCOTTI, Adam Ross PATTERSON, Richard James EDWARDS
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20230021520
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 26, 2023
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm, Michael J. Mealy
  • 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
    Patent number: 11458134
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: October 4, 2022
    Assignee: H. Lundbeck A/S
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm, Michael J. Mealy
  • Vortioxetine pyroglutamate
    Patent number: 11279682
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 22, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID
    Publication number: 20220024962
    Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
    Type: Application
    Filed: August 3, 2021
    Publication date: January 27, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez de Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fogh Jacobsen
  • Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
    Patent number: 11130775
    Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: September 28, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez de Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fog Jacobsen
  • CRYSTALLINE FORMS OF A MAGL INHIBITOR
    Publication number: 20210147367
    Abstract: Described herein is new crystalline forms of the MAGL inhibitor 2-(2-((4-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)piperazin-1-yl)methyl)-5-(trifluoromethyl)phenoxy)-2-methylpropanoic acid, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 20, 2021
    Inventors: Cheryl A. GRICE, Daniel J. BUZARD, Michael B. SHAGHAFI, Nicole S. WHITE, Heidi LOPEZ DE DIEGO, Frans Dennis THERKELSEN, Ida Marie Brødsgaard KNUDSEN
  • SOLID FORMS OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID
    Publication number: 20200392176
    Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
    Type: Application
    Filed: May 18, 2020
    Publication date: December 17, 2020
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez de Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fogh Jacobsen
  • Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
    Patent number: 10857149
    Abstract: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: December 8, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Svend Treppendahl, Heidi Lopez de Diego
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20200163959
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: July 3, 2019
    Publication date: May 28, 2020
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm
  • Vortioxetine Pyroglutamate
    Publication number: 20190210987
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt
    Type: Application
    Filed: March 6, 2019
    Publication date: July 11, 2019
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • Liquid Formulations of Salts of 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]-Piperazine
    Publication number: 20190167667
    Abstract: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.
    Type: Application
    Filed: June 27, 2018
    Publication date: June 6, 2019
    Inventors: Svend Treppendahl, Heidi Lopez de Diego
  • Vortioxetine pyroglutamate
    Patent number: 10287261
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: May 14, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
    Publication number: 20180333408
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Application
    Filed: December 18, 2017
    Publication date: November 22, 2018
    Inventors: André Faldt, Heidi Lopez de Diego, Rene Holm
  • Polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's disease
    Patent number: 10071963
    Abstract: The present invention relates to a novel polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: September 11, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Kristine Birklund Andersen, Michael Harold Rock, Heidi Lopez De Diego, Frans Dennis Therkelsen
  • Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
    Patent number: 10034876
    Abstract: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: July 31, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Svend Treppendahl, Heidi Lopez de Diego
  • Nalmefene salts as medicaments for reducing alcohol consumption or for preventing excessive alcohol consumption
    Patent number: 9938286
    Abstract: The present invention relates to new nalmefene salts which salts fall within at least one of the two following categories: non-hydrate forming salts and non-solvate forming salts. In particular, the invention relates to the hydrogen adipate salt, the hydrogen malonate salt, the lactate salt, the hydrogen fumarate salt, the hydrogen succinate salt, the benzene sulfonate salt, the hydrogen maleate salt and the salicylate salt of nalmefene. The present invention also relates to such salts for use in therapy.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: April 10, 2018
    Assignee: H. LUNDBECK A/S
    Inventor: Heidi Lopez De Diego